Biopharmaceutical company RedHill Biopharma Ltd (Nasdaq:RDHL) on Monday provided the data from its Phase 2 positive safety and efficacy data for oral opaganib in 40 hospitalised patients in the US with COVID-19 pneumonia at World Microbe Forum (WMF) 2021.
According to the company, Opaganib (Yeliva, ABC294640) is a novel and patented selective inhibitor of sphingosine kinase 2 (SK2) that is administered orally, with a unique effect demonstrated of dual anti-inflammatory and antiviral activity that targets a component of the host cell of viral replication, potentially minimizing the likelihood of viral resistance.
The company said the results and post hoc analysis of data from the phase 2 study were presented through a poster titled Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlledPhase 2A Study, in AdultSubjectsHospitalizedwith SARS-CoV-2 Positive Pneumonia ( NCT: 04414618 ).
About 86.4% of patients receiving the company's opaganib treatment were discharged from the hospital on day 14, from 55.6% of patients receiving placebo. About 81.8% of patients treated with opaganib achieved a two point improvement on the WHO Ordinal Scale, over 55.6% of patients who were part of the placebo group, achieved with a mean time of six days compared to seven and half days, respectively.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval